Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Mar;117(5):847–852. doi: 10.1111/j.1476-5381.1996.tb15270.x

Different pharmacological characteristics in L6 and C2C12 muscle cells and intact rat skeletal muscle for amylin, CGRP and calcitonin.

R A Pittner 1, D Wolfe-Lopez 1, A A Young 1, K Beaumont 1
PMCID: PMC1909412  PMID: 8851500

Abstract

1. We compared the ability of rat amylin, rat calcitonin gene-related peptide (CGRP) and rat and salmon calcitonins to elevate cyclic AMP levels and to inhibit [U-14C]-glucose incorporation into glycogen in insulin-stimulated intact rat soleus muscle and in two cell lines derived from rodent skeletal muscle, L6 and C2C12. 2. In intact soleus muscle, both amylin (EC50S of 0.7-6.1 nM) and salmon calcitonin (EC50S of 0.5-1.4 nM) were more potent than CGRP (EC50S of 5.6-15.8 nM) and were much more potent than rat calcitonin (EC50S of 50-137 nM) at stimulating cyclic AMP production, activating glycogen phosphorylase and inhibiting insulin-stimulated [14C]-glycogen formation. 3. In contrast, in both L6 and C2C12 cells, CGRP (EC50S of 0.042-0.12 nM) stimulated cyclic AMP formation and inhibited insulin-stimulated [U-14C]-glucose incorporation into glycogen approximately 1000 times more potently than amylin (EC50S 34-240 nM), while salmon calcitonin was without measurable effect. 4. There was a correlation between elevation of cyclic AMP and inhibition of insulin-stimulated [U-14C]-glucose incorporation into glycogen evoked by these peptides in both intact muscle (r2 = 0.69, P < 0.0004) and muscle cell lines (r2 = 0.96, P < 0.0001). 5. In conclusion, the effects of amylin, CGRP, and calcitonin on soleus muscle glycogen metabolism appear to be mediated by adenylyl cyclase-coupled receptors which show a pharmacological profile similar to high affinity amylin binding sites that have been previously reported in rat brain. In contrast, the effects of amylin and CGRP in L6 and C2C12 rodent muscle cell lines appear to be mediated by adenylyl cyclase-coupled receptors that behave like CGRP receptors.

Full text

PDF
847

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beaumont K., Kenney M. A., Young A. A., Rink T. J. High affinity amylin binding sites in rat brain. Mol Pharmacol. 1993 Sep;44(3):493–497. [PubMed] [Google Scholar]
  2. Beaumont K., Pittner R. A., Moore C. X., Wolfe-Lopez D., Prickett K. S., Young A. A., Rink T. J. Regulation of muscle glycogen metabolism by CGRP and amylin: CGRP receptors not involved. Br J Pharmacol. 1995 Jul;115(5):713–715. doi: 10.1111/j.1476-5381.1995.tb14991.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cooper G. J. Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr Rev. 1994 Apr;15(2):163–201. doi: 10.1210/edrv-15-2-163. [DOI] [PubMed] [Google Scholar]
  4. Cooper G. J., Leighton B., Dimitriadis G. D., Parry-Billings M., Kowalchuk J. M., Howland K., Rothbard J. B., Willis A. C., Reid K. B. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7763–7766. doi: 10.1073/pnas.85.20.7763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Deems R. O., Cardinaux F., Deacon R. W., Young D. A. Amylin or CGRP (8-37) fragments reverse amylin-induced inhibition of 14C-glycogen accumulation. Biochem Biophys Res Commun. 1991 Nov 27;181(1):116–120. doi: 10.1016/s0006-291x(05)81389-0. [DOI] [PubMed] [Google Scholar]
  6. Deems R. O., Deacon R. W., Young D. A. Amylin activates glycogen phosphorylase and inactivates glycogen synthase via a cAMP-independent mechanism. Biochem Biophys Res Commun. 1991 Jan 31;174(2):716–720. doi: 10.1016/0006-291x(91)91476-s. [DOI] [PubMed] [Google Scholar]
  7. Hue L., Bontemps F., Hers H. The effects of glucose and of potassium ions on the interconversion of the two forms of glycogen phosphorylase and of glycogen synthetase in isolated rat liver preparations. Biochem J. 1975 Oct;152(1):105–114. doi: 10.1042/bj1520105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kreutter D. K., Orena S. J., Torchia A. J., Contillo L. G., Andrews G. C., Stevenson R. W. Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor. Am J Physiol. 1993 Apr;264(4 Pt 1):E606–E613. doi: 10.1152/ajpendo.1993.264.4.E606. [DOI] [PubMed] [Google Scholar]
  9. Kreutter D., Orena S. J., Andrews K. M. Suppression of insulin-stimulated glucose transport in L6 myocytes by calcitonin gene-related peptide. Biochem Biophys Res Commun. 1989 Oct 16;164(1):461–467. doi: 10.1016/0006-291x(89)91742-7. [DOI] [PubMed] [Google Scholar]
  10. Lawrence J. C., Jr, Zhang J. N. Control of glycogen synthase and phosphorylase by amylin in rat skeletal muscle. Hormonal effects on the phosphorylation of phosphorylase and on the distribution of phosphate in the synthase subunit. J Biol Chem. 1994 Apr 15;269(15):11595–11600. [PubMed] [Google Scholar]
  11. LeBel D., Poirier G. G., Beaudoin A. R. A convenient method for the ATPase assay. Anal Biochem. 1978 Mar;85(1):86–89. doi: 10.1016/0003-2697(78)90277-4. [DOI] [PubMed] [Google Scholar]
  12. Leighton B., Cooper G. J. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature. 1988 Oct 13;335(6191):632–635. doi: 10.1038/335632a0. [DOI] [PubMed] [Google Scholar]
  13. Leighton B., Foot E. A., Cooper G. G., King J. M. Calcitonin gene-related peptide-1 (CGRP-1) is a potent regulator of glycogen metabolism in rat skeletal muscle. FEBS Lett. 1989 Jun 5;249(2):357–361. doi: 10.1016/0014-5793(89)80658-1. [DOI] [PubMed] [Google Scholar]
  14. Pittner R. A., Albrandt K., Beaumont K., Gaeta L. S., Koda J. E., Moore C. X., Rittenhouse J., Rink T. J. Molecular physiology of amylin. J Cell Biochem. 1994;55 (Suppl):19–28. doi: 10.1002/jcb.240550004. [DOI] [PubMed] [Google Scholar]
  15. Pittner R. A., Wolfe-Lopez D., Young A. A., Rink T. J. Amylin and epinephrine have no direct effect on glucose transport in isolated rat soleus muscle. FEBS Lett. 1995 May 22;365(1):98–100. doi: 10.1016/0014-5793(95)00449-j. [DOI] [PubMed] [Google Scholar]
  16. Poyner D. R., Andrew D. P., Brown D., Bose C., Hanley M. R. Pharmacological characterization of a receptor for calcitonin gene-related peptide on rat, L6 myocytes. Br J Pharmacol. 1992 Feb;105(2):441–447. doi: 10.1111/j.1476-5381.1992.tb14272.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rink T. J., Beaumont K., Koda J., Young A. Structure and biology of amylin. Trends Pharmacol Sci. 1993 Apr;14(4):113–118. doi: 10.1016/0165-6147(93)90081-t. [DOI] [PubMed] [Google Scholar]
  18. Rossetti L., Farrace S., Choi S. B., Giaccari A., Sloan L., Frontoni S., Katz M. S. Multiple metabolic effects of CGRP in conscious rats: role of glycogen synthase and phosphorylase. Am J Physiol. 1993 Jan;264(1 Pt 1):E1–10. doi: 10.1152/ajpendo.1993.264.1.E1. [DOI] [PubMed] [Google Scholar]
  19. Sexton P. M., Paxinos G., Kenney M. A., Wookey P. J., Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience. 1994 Sep;62(2):553–567. doi: 10.1016/0306-4522(94)90388-3. [DOI] [PubMed] [Google Scholar]
  20. Shainberg A., Yagil G., Yaffe D. Alterations of enzymatic activities during muscle differentiation in vitro. Dev Biol. 1971 May;25(1):1–29. doi: 10.1016/0012-1606(71)90017-0. [DOI] [PubMed] [Google Scholar]
  21. Sheriff S., Fischer J. E., Balasubramaniam A. Amylin inhibits insulin-stimulated glucose uptake in C2C12 muscle cell line through a cholera-toxin-sensitive mechanism. Biochim Biophys Acta. 1992 Aug 12;1136(2):219–222. doi: 10.1016/0167-4889(92)90260-i. [DOI] [PubMed] [Google Scholar]
  22. Stalmans W., Hers H. G. The stimulation of liver phosphorylase b by AMP, fluoride and sulfate. A technical note on the specific determination of the a and b forms of liver glycogen phosphorylase. Eur J Biochem. 1975 Jun;54(2):341–350. doi: 10.1111/j.1432-1033.1975.tb04144.x. [DOI] [PubMed] [Google Scholar]
  23. Yaffe D. Retention of differentiation potentialities during prolonged cultivation of myogenic cells. Proc Natl Acad Sci U S A. 1968 Oct;61(2):477–483. doi: 10.1073/pnas.61.2.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Yamaguchi A., Chiba T., Okimura Y., Yamatani T., Morishita T., Nakamura A., Inui T., Noda T., Fujita T. Receptors for calcitonin gene-related peptide on the rat liver plasma membranes. Biochem Biophys Res Commun. 1988 Apr 15;152(1):383–391. doi: 10.1016/s0006-291x(88)80725-3. [DOI] [PubMed] [Google Scholar]
  25. Young A. A., Gedulin B., Wolfe-Lopez D., Greene H. E., Rink T. J., Cooper G. J. Amylin and insulin in rat soleus muscle: dose responses for cosecreted noncompetitive antagonists. Am J Physiol. 1992 Aug;263(2 Pt 1):E274–E281. doi: 10.1152/ajpendo.1992.263.2.E274. [DOI] [PubMed] [Google Scholar]
  26. Young D. A., Deems R. O., Deacon R. W., McIntosh R. H., Foley J. E. Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol. 1990 Sep;259(3 Pt 1):E457–E461. doi: 10.1152/ajpendo.1990.259.3.E457. [DOI] [PubMed] [Google Scholar]
  27. Zhu G. C., Dudley D. T., Saltiel A. R. Amylin increases cyclic AMP formation in L6 myocytes through calcitonin gene-related peptide receptors. Biochem Biophys Res Commun. 1991 Jun 14;177(2):771–776. doi: 10.1016/0006-291x(91)91855-7. [DOI] [PubMed] [Google Scholar]
  28. van Rossum D., Ménard D. P., Fournier A., St-Pierre S., Quirion R. Autoradiographic distribution and receptor binding profile of [125I]Bolton Hunter-rat amylin binding sites in the rat brain. J Pharmacol Exp Ther. 1994 Aug;270(2):779–787. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES